港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医药外包概念

1,793.042

+20.8101.17%

涨家数：4

跌家数：4

平家数：- -

市盈率：- -

高：1,835.570

开：1,770.415

低：1,747.549

收：1,772.232

数据加载中...

昆药集团(600422.SH)：天麻素注射液临床试验获批准

泰格医药02月28日遭主力抛售483万元

昭衍新药02月28日遭主力抛售492万元

维亚生物(01873)股价下跌9.091%，现价港币$1.3

阿斯达克财经

泰格医药盘中异动下午盘急速跳水5.09%报34.500港元

维亚生物盘中异动下午盘快速跳水5.59%

金斯瑞生物科技盘中异动下午盘快速跳水5.13%

药明生物(02269)下跌5.07%，报22.45元/股

药明生物盘中异动股价大跌5.07%

康龙化成盘中异动股价大跌5.11%报15.980港元

昭衍新药盘中异动早盘快速跳水5.40%

药明康德盘中异动早盘大幅下跌3.03%报60.800港元

复星医药(02196.HK)子公司获药品临床试验批准

阿斯达克财经

复星医药(02196)：星盛新辉收到国家药监局关于同意XS-03片的药品临床试验批准

【众生药业：控股子公司获得一类创新药RAY1225注射液III期临床试验伦理批件】金融界2月27日消息，近日，众生药业控股子公司众生睿创自主研发的一类创新多肽药物RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验获得组长单位北京大学人民医院和共同组长单位中山大学孙逸仙纪念医院伦理审查批件，批准项目开展。RAY1225注射液是具有全球自主知识产权的创新结构多肽药物，属于长效GLP-1类药物，具有双重激动活性，可调节人体代谢和控制血糖。本次III期临床试验组长单位伦理批件的获得，标志着该试验将全面启动。该注射液获得伦理批件对公司短期财务状况和经营业绩不构成重大影响，但临床试验存在风险和不确定性，公司将按规定履行信息披露义务。

【众生药业：RAY1225注射液III期临床试验伦理批件获批】众生药业公告，控股子公司众生睿创自主研发的RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验(REBUILDING-2)获得组长单位北京大学人民医院和共同组长单位中山大学孙逸仙纪念医院伦理审查批件，批准项目开展。RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，属于长效GLP-1类药物，具有GLP-1受体和GIP受体双重激动活性，可通过刺激胰岛素分泌、延缓胃排空等机制调节人体代谢和控制血糖，有望用于降糖、减肥、代谢综合征等多种代谢性疾病的治疗。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1576/news?page=8"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"医药外包概念","latestPrice":1793.0419,"timestamp":1741334919514,"preClose":1772.232,"halted":0,"volume":105965997,"delay":0,"changeRate":0.011742,"change":20.809814,"pbRate":2.65369,"amount":2334342230,"amplitude":0.049667,"prevYearClose":1395.7731,"fiveDayClose":1699.456,"twentyDayClose":1588.191,"turnoverRate":0.008873,"marketCap":381645564416,"floatMarketCap":165840598400,"peRate":33.079805},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1835.5696,"amplitude":0.049667,"preClose":1772.232,"low":1747.5487,"pbRate":"2.65369","latestPrice":1793.0419,"volume":105965997,"delay":0,"open":1770.415,"prevYearClose":1395.7731,"prevWeekClose":1699.456,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1699.456,"twentyDayClose":1588.191,"sixtyDayClose":1337.64,"secType":"PLATE","market":"HK","turnoverRate":0.008873,"peRate":33.079805,"marketCap":381645564416,"floatMarketCap":165840598400,"timestamp":1741334919514,"nameCN":"医药外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":4,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514435243","title":"昆药集团(600422.SH)：天麻素注射液临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514435243","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514435243?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 17:15","pubTimestamp":1740734140,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昆药集团(600422.SH)公告，公司近日收到国家药品监督管理局签发的天麻素注射液按照化学药品2.4类新药受理的《药物临床试验批准通知书》，同意该新药开展相关临床试验研究，该新药适应症为：预防心脏外科术后谵妄。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","600422","BK1576","BK1583","BK0239","03347","BK0188","BK0028","BK0060"],"gpt_icon":0},{"id":"2514348825","title":"泰格医药02月28日遭主力抛售483万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514348825","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514348825?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 16:17","pubTimestamp":1740730640,"startTime":"0","endTime":"0","summary":"02月28日, 泰格医药股价跌6.88%，报收33.85元，成交金额1.78亿元，换手率4.16%，振幅9.90%，量比0.71。泰格医药今日主力资金净流出483万元，上一交易日主力净流出37万元。该股近5个交易日下跌13.08%，主力资金累计净流出2704万元；近20日主力资金累计净流入1251万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228165711a2579d8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228165711a2579d8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","03347","BK1583"],"gpt_icon":0},{"id":"2514348385","title":"昭衍新药02月28日遭主力抛售492万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514348385","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514348385?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 16:16","pubTimestamp":1740730597,"startTime":"0","endTime":"0","summary":"02月28日, 昭衍新药股价跌15.04%，报收13.22元，成交金额8936万元，换手率5.41%，振幅17.74%，量比0.86。昭衍新药今日主力资金净流出492万元，上一交易日主力净流出145万元。该股近5个交易日下跌2.81%，主力资金累计净流出88万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入2110万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228165606a2579d0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228165606a2579d0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06127","BK1576","BK1141"],"gpt_icon":0},{"id":"2514397299","title":"维亚生物(01873)股价下跌9.091%，现价港币$1.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2514397299","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514397299?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 14:25","pubTimestamp":1740723900,"startTime":"0","endTime":"0","summary":"[下跌股]维亚生物(01873) 股价在下午02:25比前收市价下跌9.091%，现股价为港币$1.3。至目前为止，今日最高价为$1.43，而最低价为$1.3。总成交量为320.2万股，总成交金额为港币$438.336万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2502286799/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1141","BK1576","01873"],"gpt_icon":0},{"id":"2514391159","title":"泰格医药盘中异动 下午盘急速跳水5.09%报34.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514391159","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514391159?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 13:38","pubTimestamp":1740721101,"startTime":"0","endTime":"0","summary":"2025年02月28日下午盘13时38分，泰格医药股票出现波动，股价快速跳水5.09%。截至发稿，该股报34.500港元/股，成交量251.09万股，换手率2.04%，振幅6.74%。资金方面，该股资金流入3535.17万港元，流出4007.46万港元。最近的财报数据显示，该股实现营业收入56.20亿港元，净利润9.02亿港元，每股收益1.04港元，毛利21.85亿港元，市盈率13.34倍。泰格医药股票所在的生物技术行业中，整体跌幅为0.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502281338219895dcd2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502281338219895dcd2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","BK1583","03347"],"gpt_icon":0},{"id":"2514539417","title":"维亚生物盘中异动 下午盘快速跳水5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514539417","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514539417?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 13:20","pubTimestamp":1740720002,"startTime":"0","endTime":"0","summary":"2025年02月28日下午盘13时20分，维亚生物股票出现波动，股价快速下跌5.59%。截至发稿，该股报1.350港元/股，成交量247.45万股，换手率0.12%，振幅5.59%。资金方面，该股资金流入135.189万港元，流出194.393万港元。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。维亚生物股票所在的生物技术行业中，整体跌幅为0.05%。维亚生物公司简介：维亚生物科技控股集团是一家投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228132002a2575429&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228132002a2575429&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","01873","BK1141"],"gpt_icon":0},{"id":"2514399941","title":"金斯瑞生物科技盘中异动 下午盘快速跳水5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514399941","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514399941?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 13:11","pubTimestamp":1740719483,"startTime":"0","endTime":"0","summary":"2025年02月28日下午盘13时11分，金斯瑞生物科技股票出现波动，股价急速跳水5.13%。截至发稿，该股报12.580港元/股，成交量1180.31万股，换手率0.55%，振幅5.73%。金斯瑞生物科技股票所在的生物技术行业中，整体涨幅为0.10%。金斯瑞生物科技公司简介：金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228131123abe03ff3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228131123abe03ff3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","HK0000320223.HKD","HK0000306685.HKD","01548","HK0000320264.USD","BK1583","HK0000306701.USD"],"gpt_icon":0},{"id":"2514360108","title":"药明生物(02269)下跌5.07%，报22.45元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2514360108","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514360108?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 11:20","pubTimestamp":1740712824,"startTime":"0","endTime":"0","summary":"2月28日，药明生物(02269)盘中下跌5.07%，截至11:20，报22.45元/股，成交6.66亿元。药明生物技术有限公司是全球领先的生物制剂服务供应商，提供全面、综合及高度定制的服务，包括从发现、开发到生产生物制剂的全过程。公司在2016年在中国生物制剂研发市场占有48%的市场份额，已与全球20大制药公司中的12家建立合作关系。截至2024年中报，药明生物营业总收入85.74亿元、净利润14.99亿元。3月25日，药明生物将披露2024财年年报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/28112048448598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0052750758.USD","LU0708995583.HKD","LU0307460666.USD","LU0516422366.SGD","LU0417516902.SGD","SG9999002562.SGD","LU0516423174.USD","IE00B0JY6N72.USD","LU0181495838.USD","LU0039217434.USD","LU0516422440.USD","LU0856984785.SGD","LU1720050803.USD","BK1589","BK1576","LU0417516738.SGD","LU0979878070.USD","LU0819121731.USD","LU0823426308.USD","BK1610","LU1242518931.SGD","LU0348735423.USD","LU0326950275.SGD","BK1141","LU0588546209.SGD","BK1521","LU0043850808.USD","LU0140636845.USD","LU0327786744.USD","LU0348825331.USD","LU0320764599.SGD","LU0456827905.SGD","LU1242518857.USD","LU1880383366.USD","LU0359202008.SGD","SG9999002463.SGD","LU1794554557.SGD","LU0516423091.SGD","LU0051755006.USD","02269","LU0359201612.USD","LU0456846285.SGD","LU0516422952.EUR","LU0572944931.SGD","LU0823426480.USD","LU2039709279.SGD","LU1688375341.USD"],"gpt_icon":0},{"id":"2514589360","title":"药明生物盘中异动 股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514589360","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514589360?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 11:20","pubTimestamp":1740712822,"startTime":"0","endTime":"0","summary":"2025年02月28日早盘11时20分，药明生物股票出现波动，股价快速跳水5.07%。截至发稿，该股报22.450港元/股，成交量2900.51万股，换手率0.71%，振幅5.07%。资金方面，该股资金流入2.45638亿港元，流出3.71824亿港元。药明生物股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，迈博药业-B、帝王国际投资、奥星生命科技涨幅较大，振幅较大的相关个股有帝王国际投资、科笛-B、昭衍新药，振幅分别为23.08%、16.33%、13.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502281120229895bbd9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502281120229895bbd9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417516902.SGD","LU1720050803.USD","LU0417516738.SGD","LU0572944931.SGD","LU0327786744.USD","LU0051755006.USD","02269","LU0052750758.USD","LU0823426480.USD","IE00B0JY6N72.USD","LU0140636845.USD","LU0348735423.USD","LU0516423174.USD","LU1688375341.USD","SG9999002562.SGD","BK1610","LU1242518931.SGD","SG9999002463.SGD","LU0823426308.USD","LU0708995583.HKD","LU1242518857.USD","BK1576","LU0348825331.USD","LU0359202008.SGD","LU0307460666.USD","LU0516422440.USD","LU0856984785.SGD","LU0039217434.USD","LU1880383366.USD","LU0326950275.SGD","LU0516422366.SGD","LU0359201612.USD","LU0043850808.USD","LU0516422952.EUR","BK1141","LU1794554557.SGD","LU0819121731.USD","LU0181495838.USD","LU0516423091.SGD","LU0588546209.SGD","LU0320764599.SGD","LU2039709279.SGD","BK1589","LU0456846285.SGD","LU0456827905.SGD","LU0979878070.USD","BK1521"],"gpt_icon":1},{"id":"2514364584","title":"康龙化成盘中异动 股价大跌5.11%报15.980港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514364584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514364584?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 10:17","pubTimestamp":1740709026,"startTime":"0","endTime":"0","summary":"2025年02月28日早盘10时17分，康龙化成股票出现异动，股价急速跳水5.11%。截至发稿，该股报15.980港元/股，成交量318.08万股，换手率1.08%，振幅4.99%。资金方面，该股资金流入1074.81万港元，流出3151.3万港元。康龙化成股票所在的药品行业中，整体跌幅为0.65%。其相关个股中，君圣泰医药-B、海王英特龙、草姬集团涨幅较大，振幅较大的相关个股有德琪医药-B、开拓药业-B、艾美疫苗，振幅分别为17.48%、11.67%、7.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022810170796334b74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022810170796334b74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03759","BK1141","BK1576"],"gpt_icon":0},{"id":"2514836696","title":"昭衍新药盘中异动 早盘快速跳水5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514836696","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514836696?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 09:38","pubTimestamp":1740706715,"startTime":"0","endTime":"0","summary":"2025年02月28日早盘09时38分，昭衍新药股票出现异动，股价快速跳水5.40%。截至发稿，该股报14.720港元/股，成交量25.34万股，换手率0.21%，振幅7.58%。昭衍新药股票所在的生物技术行业中，整体涨幅为1.61%。其相关个股中，百济神州、永泰生物-B、华昊中天医药-B涨幅较大，振幅较大的相关个股有科笛-B、永泰生物-B、创胜集团-B，振幅分别为11.71%、10.40%、8.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228093835abe00558&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228093835abe00558&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","06127"],"gpt_icon":0},{"id":"2514636662","title":"药明康德盘中异动 早盘大幅下跌3.03%报60.800港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514636662","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514636662?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 09:37","pubTimestamp":1740706637,"startTime":"0","endTime":"0","summary":"2025年02月28日早盘09时37分，药明康德股票出现波动，股价急速跳水3.03%。截至发稿，该股报60.800港元/股，成交量49.1656万股，换手率0.13%，振幅2.63%。资金方面，该股资金流入769.087万港元，流出1732.96万港元。药明康德股票所在的生物技术行业中，整体涨幅为1.61%。其相关个股中，百济神州、永泰生物-B、华昊中天医药-B涨幅较大，振幅较大的相关个股有科笛-B、永泰生物-B、创胜集团-B，振幅分别为11.71%、10.40%、8.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022809371798959ab7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022809371798959ab7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2242644610.SGD","LU2125910500.SGD","LU2045819591.USD","LU1046422090.SGD","LU0320764599.SGD","BK1576","02359","BK1141","LU0052750758.USD","BK1583","LU0708995583.HKD"],"gpt_icon":0},{"id":"2514891423","title":"复星医药(02196.HK)子公司获药品临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514891423","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514891423?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 23:16","pubTimestamp":1740669360,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，控股子公司星盛新辉收到国家药品监督管理局关于同意 XS-03片与FOLFOX 或FOLFIRI和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌临床试验的批准。该治疗方案中所涉XS-03为集团自主研发的小分子口服PLK1 抑制剂。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-27 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420857/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0012","BK0188","BK0239","BK1593","BK0196","03347","BK1583","BK0187","BK0028","BK1141","02196","BK0096","BK0175","BK0060","BK0183","600196","BK1515","BK1191","BK1576"],"gpt_icon":0},{"id":"2514492874","title":"复星医药(02196)：星盛新辉收到国家药监局关于同意XS-03片的药品临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514492874","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514492874?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 18:42","pubTimestamp":1740652968,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，该公司控股子公司江苏星盛新辉医药有限公司于近日收到国家药品监督管理局关于同意XS-03片与FOLFOX或FOLFIRI 和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌临床试验的批准。截至目前的研究显示，XS-03 在多种肿瘤模型中展现较为显著的抑制肿瘤生长的药效，且临床安全性良好。截至本公告日期，XS-03 单药用于治疗RAS突变晚期实体瘤于中国境内处于I期临床试验阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0175","BK0183","02196","BK1583","BK0188","600196","BK1576","BK1141","BK1515","BK0196","BK1191","BK0060","BK0096","03347","BK0187","BK0239","BK0012","BK1593"],"gpt_icon":0},{"id":"2514798938","title":"【众生药业：控股子公司获得一类创新药RAY1225注射液III期临床试验伦理批件】金融界2月27日消息，近日，众生药业控股子公司众生睿创自主研发的一类创新多肽药物RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验获得组长单位北京大学人民医院和共同组长单位中山大学孙逸仙纪念医院伦理审查批件，批准项目开展。RAY1225注射液是具有全球自主知识产权的创新结构多肽药物，属于长效GLP-1类药物，具有双重激动活性，可调节人体代谢和控制血糖。本次III期临床试验组长单位伦理批件的获得，标志着该试验将全面启动。该注射液获得伦理批件对公司短期财务状况和经营业绩不构成重大影响，但临床试验存在风险和不确定性，公司将按规定履行信息披露义务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514798938","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514798938?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 17:56","pubTimestamp":1740650165,"startTime":"0","endTime":"0","summary":"金融界2月27日消息，近日，众生药业控股子公司众生睿创自主研发的一类创新多肽药物RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验获得组长单位北京大学人民医院和共同组长单位中山大学孙逸仙纪念医院伦理审查批件，批准项目开展。本次III期临床试验组长单位伦理批件的获得，标志着该试验将全面启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27175648431102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1141","BK4134","BK4144","03347","BK1583","BK1161","BK1576","GLP","III","BK4590","BK0188","BK0239","159992","BK0077","06978","002317"],"gpt_icon":0},{"id":"2514879859","title":"【众生药业：RAY1225注射液III期临床试验伦理批件获批】众生药业公告，控股子公司众生睿创自主研发的RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验(REBUILDING-2)获得组长单位北京大学人民医院和共同组长单位中山大学孙逸仙纪念医院伦理审查批件，批准项目开展。RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，属于长效GLP-1类药物，具有GLP-1受体和GIP受体双重激动活性，可通过刺激胰岛素分泌、延缓胃排空等机制调节人体代谢和控制血糖，有望用于降糖、减肥、代谢综合征等多种代谢性疾病的治疗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514879859","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514879859?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 17:55","pubTimestamp":1740650130,"startTime":"0","endTime":"0","summary":"众生药业公告，控股子公司众生睿创自主研发的RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验(REBUILDING-2)获得组长单位北京大学人民医院和共同组长单位中山大学孙逸仙纪念医院伦理审查批件，批准项目开展。RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，属于长效GLP-1类药物，具有GLP-1受体和GIP受体双重激动活性，可通过刺激胰岛素分泌、延缓胃排空等机制调节人体代谢和控制血糖，有望用于降糖、减肥、代谢综合征等多种代谢性疾病的治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27175548431160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","BK1141","GLP","BK0239","III","BK4134","BK1576","002317","BK0077","03347","BK4144","BK4590","BK1583"],"gpt_icon":0}],"pageSize":16,"totalPage":14,"pageCount":8,"totalSize":218}]}}